Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Seminars in Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 11842387
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

  1999cited by this paper
• Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

  1999cited by this paper
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

  1997cited by this paper
• Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.

  1996cited by this paper

• Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells

  2016cites this paper
• Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients

  2007cites this paper
• Grading follicular lymphoma on fine‐needle aspiration specimens—A practical approach

  2006cites this paper
• The role of mitoxantrone in the treatment of indolent lymphomas.

  2005cites this paper
• Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t

  2005cites this paper
• Detection of Two Cell Populations Corresponding to Distinct Maturation Stages in API-2/MLT-Positive Mucosa-Associated Lymphoid Tissue Lymphoma Cells Proliferating in Pleural Effusion

  2003cites this paper